1 active not recruiting, 1 not yet recruiting, 1 recruiting, 1 terminated. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Not yet recruiting 1 |
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
Follow Renal Cell Cancer, Recurrent: new trials by email Literature Review of Renal Cell Cancer, Recurrent trials Research Report on Renal Cell Cancer, Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-10-15 | 2026-10-13 |
| Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-03-25 | 2026-04-01 |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Belzutifan, Cabozantinib - Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 2 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 118 | 2018-09-27 | 2024-12-20 |
| Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy Concomitant coaching - Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent | Phase 3 | Terminated | AIO-Studien-gGmbH | 121 | 2017-01-18 | 2025-02-14 |
Carcinoma, Renal Cell (4) · Recurrence (4) · Kidney Neoplasms (3) · Neoplasm Metastasis (1)
Adenocarcinoma (4) · Carcinoma (4) · Disease Attributes (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Kidney Diseases (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4)
belzutifan (1) · cabozantinib (1)
Telix Pharmaceuticals (Innovations) Pty Limited (2) · AIO-Studien-gGmbH (1) · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
United States (2) · Australia (1) · Germany (1)
PMID 22980441, PMID 26706103, PMID 37011650, PMID 39756444
2016 (1), 2025 (1)